0.145 USD
-0.07 (-32.59%)
0.1379 USD
-0.01 (-4.9%)
We assign a fundamental rating of 1 out of 10 to GRTX. GRTX was compared to 525 industry peers in the Biotechnology industry. GRTX may be in some trouble as it scores bad on both profitability and health. GRTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year GRTX has reported negative net income.
- GRTX had a negative operating cash flow in the past year.
- In the past 5 years GRTX always reported negative net income.
- GRTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -232.80%, GRTX is doing worse than 91.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -232.8% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-154.7%
ROA(5y)-120.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for GRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, GRTX has more shares outstanding
- Compared to 1 year ago, GRTX has a worse debt to assets ratio.
2.2 Solvency
- GRTX has an Altman-Z score of -36.96. This is a bad value and indicates that GRTX is not financially healthy and even has some risk of bankruptcy.
- GRTX has a Altman-Z score of -36.96. This is amonst the worse of the industry: GRTX underperforms 93.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -36.96 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- GRTX has a Current Ratio of 7.54. This indicates that GRTX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of GRTX (7.54) is better than 67.76% of its industry peers.
- GRTX has a Quick Ratio of 7.54. This indicates that GRTX is financially healthy and has no problem in meeting its short term obligations.
- GRTX has a Quick ratio of 7.54. This is in the better half of the industry: GRTX outperforms 67.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.54 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 55.27% over the past year.
EPS 1Y (TTM)55.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- GRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.30% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.72%
EPS Next 2Y25.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- GRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year GRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as GRTX's earnings are expected to grow with 25.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.3%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for GRTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GALERA THERAPEUTICS INC / GRTX FAQ
What is the ChartMill fundamental rating of GALERA THERAPEUTICS INC (GRTX) stock?
ChartMill assigns a fundamental rating of 1 / 10 to GRTX.
What is the valuation status for GRTX stock?
ChartMill assigns a valuation rating of 1 / 10 to GALERA THERAPEUTICS INC (GRTX). This can be considered as Overvalued.
What is the profitability of GRTX stock?
GALERA THERAPEUTICS INC (GRTX) has a profitability rating of 0 / 10.